Novavax, Inc. (NASDAQ:NVAX) insider Stanley C. Erck bought 100,000 shares of the company’s stock in a transaction on Thursday, November 9th. The stock was bought at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the purchase, the insider now directly owns 228,279 shares in the company, valued at $257,955.27. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Novavax, Inc. (NASDAQ NVAX) traded down $0.01 during trading hours on Monday, reaching $1.12. 2,289,400 shares of the company were exchanged, compared to its average volume of 5,938,572. Novavax, Inc. has a 12 month low of $0.73 and a 12 month high of $1.78. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The company had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share. Novavax’s revenue for the quarter was up 158.5% compared to the same quarter last year. equities analysts anticipate that Novavax, Inc. will post -0.61 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/novavax-inc-nvax-insider-acquires-113000-00-in-stock/1700521.html.

Several equities research analysts have recently weighed in on NVAX shares. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Wednesday, August 16th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price target on shares of Novavax in a research report on Wednesday, November 8th. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Seaport Global Securities reaffirmed a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Finally, Chardan Capital reaffirmed a “neutral” rating and issued a $1.50 price target on shares of Novavax in a research report on Thursday, July 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $3.12.

A number of large investors have recently bought and sold shares of NVAX. Vanguard Group Inc. raised its holdings in shares of Novavax by 4.5% in the first quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after buying an additional 938,581 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Novavax by 40.1% in the second quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company’s stock worth $5,976,000 after buying an additional 1,488,403 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Novavax by 2.8% in the second quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company’s stock worth $3,883,000 after buying an additional 92,854 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Novavax by 18.3% in the first quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock worth $3,073,000 after buying an additional 371,295 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Novavax by 38.7% in the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock worth $1,944,000 after buying an additional 471,347 shares during the last quarter. 38.87% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.